Low risk, very high reward I think, I rate monkey tox passing and FDA lifting hold a major catalyst for the company success
Optimists could see things starting to align...
- Monkeys suddenly available and we got in at a good time
- Monkey Data crucial to US partner ticking off on deal, one would think
- monkey data out pre trial results
- Cleaning up share register
- Competitor stumbling
- ANP starting to look compelling to a partner, more so every day as we approach mid 2024
Are there enough boxes being ticked? time will tell
Low risk, very high reward I think, I rate monkey tox passing...
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.005(5.00%) |
Mkt cap ! $99.16M | |||
| Open | High | Low | Value | Volume |
| 11.0¢ | 11.5¢ | 10.5¢ | $167.1K | 1.532M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 563549 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 382827 | 5 |
View Market Depth
| Last trade - 13.48pm 30/09/2024 (20 minute delay) ? |
| PER (ASX) Chart |